Skip to main contentSkip to main content
info@smcsalud.org
Diabetic Foot Treatment (Heberprot-P)
Endocrinology

Diabetic Foot Treatment (Heberprot-P)

A growth factor therapy that helps heal diabetic foot ulcers and lower the risk of amputation.

Request Consultation
Diabetic Foot Treatment (Heberprot-P)
Featured Cuban medication / vaccine

Diabetic Foot Treatment (Heberprot-P)

A growth factor therapy that helps heal diabetic foot ulcers and lower the risk of amputation.

Read our in-depth guide: Diabetic Foot Ulcer

Symptoms, diagnosis, stages, Cuban treatment approach, eligibility & costs

Heberprot-P is a unique Cuban biotechnology product. It contains a recombinant (lab-made) human Epidermal Growth Factor (hEGF) — a protein that helps skin and tissue cells grow and heal. It is given by injection directly into the edges of complex diabetic foot ulcers (open wounds on the feet that are hard to heal). Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, it offers a treatment option for wounds that have not responded to standard care.

Your Patient Journey

What to expect before, during, and after your treatment in Cuba.

  1. Step 1

    Before You Arrive

    Send your medical records for review. Our coordination team confirms eligibility, builds a personalized plan, and assists with visa and travel arrangements.

    • Free remote medical records evaluation
    • Visa and travel coordination
    • Personalized treatment plan
  2. Step 2

    During Treatment

    Receive your treatment at one of our partner centers in Havana. A dedicated coordinator supports you at every appointment and procedure.

    • Admission to partner center
    • Specialist consultations and procedures
    • On-site coordinator support
  3. Step 3

    Aftercare & Recovery

    Continue your recovery with a structured discharge plan, follow-up coordination, and remote check-ins with your Cuban medical team once you return home.

    • Structured discharge and care plan
    • Follow-up appointment scheduling
    • Remote check-ins with your team

Outcomes & Recovery

An overview of documented outcomes and what to expect during and after treatment. Individual results vary and are confirmed during your personalized evaluation.

Success Rates & Experience

26+Countries where Heberprot-P is registered
SignificantHealing in ulcers unresponsive to standard care
ReducedRisk of amputation with growth-factor therapy
AcceleratedWound healing and tissue granulation

Typical Recovery Timeline

Injections three times per week for up to 8 weeks, with comprehensive wound care
  1. Assessment

    Wound grading (Wagner/UT), vascular and neurological evaluation confirm suitability.

  2. Injection therapy

    Intralesional Heberprot-P three times weekly, combined with debridement, offloading and infection control.

  3. Wound closure & follow-up

    Monitoring until closure, with glycemic control and a home-care plan to prevent recurrence.

These figures reflect clinical experience and published studies. Individual results vary and are confirmed during a personalized medical evaluation.

How We Compare

Cuban Biotech vs. Standard International Care

A side-by-side look at what makes this treatment distinctive compared with conventional options abroad.

Treatment approach

SMC Salud (Cuba)

Intralesional recombinant human EGF (Heberprot-P) injected directly into the wound edges.

Standard International Care

Standard wound care: debridement, dressings, offloading, and antibiotics.

Mechanism of action

SMC Salud (Cuba)

Delivers growth factor to the wound site to stimulate cellular proliferation and tissue regeneration.

Standard International Care

Manages symptoms and infection but offers no pro-healing biological agent.

Amputation risk

SMC Salud (Cuba)

Developed specifically to reduce amputation in ulcers that fail conventional care.

Standard International Care

High amputation rates once standard wound care has failed.

Healing reach

SMC Salud (Cuba)

Can heal complex ulcers (Wagner grade 2–4) that are unresponsive to standard therapy.

Standard International Care

Limited options for non-healing wounds.

Registration & scale

SMC Salud (Cuba)

Registered in 26+ countries and used in thousands of patients worldwide.

Standard International Care

No comparable growth-factor product widely available internationally.

Administration

SMC Salud (Cuba)

Specialist-administered 3× per week for up to 8 weeks, with full diabetes management.

Standard International Care

Variable outpatient wound-clinic visits with no standardized biological protocol.

Frequently Asked Questions

Find answers about the medical procedure and the full range of patient support services we provide for this treatment.

About the Procedure — Diabetic Foot Treatment (Heberprot-P)

Patient Support Services

Cuban Biotech Therapies

Medically Reviewed

SMC Salud Medical Review Board

Board-certified physicians and specialists in oncology, neurology, dermatology, and endocrinology

Last reviewed: January 15, 2025

This content has been medically reviewed by qualified physicians and follows SMC Salud's editorial policy for health information. Medical content is for informational purposes and does not replace professional medical advice.

Ready to Learn More?

Take the next step. Our international patient coordinators are here to help you understand your options.

Treatment suitability depends on specialist evaluation. Individual treatment plans apply.